The opinion concludes that ‘Oxy’Pharm H2O2’ is a biocidal product family within the meaning of Article 3(1), point (s), of Regulation (EU) No 528/2012, that it is eligible for Union authorisation in accordance with Article 42(1) of that Regulation and that subject to compliance with the draft SPC, it meets the conditions laid down in Article 19(1) and (6) of that Regulation.
Recital 5, Regulation (EU) 2023/1764
In forcesince 12 Sep 2023